

## **Supplementary Materials**

**Supplementary Table 1. Comparison of baseline characteristics and outcome between non-infectious-related and HCV-related MC glomerulonephritis.**

	Non-infectious MC glomerulonephritis n=80	HCV (+) MC glomerulonephritis n=34	<i>P</i>
<b>Epidemiological data</b>			
- Age at diagnosis (years), mean ± SD	62.6 ± 14.1	58.8 ± 13.3	0.19
- Women, n (%)	50 (62.5)	14 (41.2)	0.06
<b>Extrarenal manifestations at presentation</b>			
- Skin lesions, n (%)	57 (71.3)	23 (67.6)	0.87
- Purpura, n (%)	55 (68.8)	22 (64.7)	0.84
- Ulcers, n (%)	6 (7.5)	1 (2.9)	0.62
- Necrosis, n (%)	1 (1.3)	1 (2.9)	0.88
- Peripheral neuropathy, n (%)	34 (42.5)	19 (55.9)	0.27
- Arthralgias/Arthritis, n (%)	28 (35)	11 (32.4)	0.95
- Gut vasculitis, n (%)	9 (11.3)	3 (8.8)	0.96
- CNS involvement, n (%)	1 (1.3)	7 (20.6)	<b>0.001</b>
<b>Biological features at presentation</b>			
- Type II MC, n (%)	75 (97.4)	28 (82.4)	<b>0.02</b>
- Hypocomplementemia, n (%)	57 (81.4)	26 (76.5)	0.74
<b>Renal parameters at presentation</b>			
- Hypertension, n (%)	58 (85.3)	25 (73.5)	0.24
- Proteinuria, mean ± SD	3.5 ± 3	4.3 ± 4.0	0.22
- ≥ 1 g/d, n (%)	67 (84.8)	30 (88.2)	0.58
- ≥ 3 g/d, n (%)	39 (49.4)	22 (64.7)	0.14
- Hematuria, n (%)	66 (97.4)	27 (79.4)	<b>0.005</b>
- Serum creatinine, mean ± SD	173.0 ± 108.7	202.3 ± 178.1	0.29
- eGFR, mean ± SD	39.5 ± 20.4	43.9 ± 27.5	0.35
- < 60 mL/min/1.73 m <sup>2</sup> , n (%)	65 (82.3)	24 (70.6)	0.25
- Dialysis, n (%)	4 (5.1)	1 (2.9)	0.78
<b>Follow-up</b> (months), mean ± SD	49.9 ± 45.5	26.9 ± 23.9	<b>0.006</b>
<b>Relapses</b> , n (%)	32 (42.7)	10 (29.4)	0.27
- Delay to 1 <sup>st</sup> relapse (months), mean ± SD	28.2 ± 19.4	5.7 ± 7.0	<b>0.002</b>
<b>Administered Treatments</b>			
- Antiviral treatment	-	33 (97.1)	
- Steroids, n (%)	75 (98.7)	15 (44.1)	<b>&lt;0.0001</b>
- Steroids alone, n (%)	12 (15.8)	0 (0.0)	<b>0.03</b>
- Rituximab, n (%)	41 (53.9)	22 (64.7)	0.40
- Cyclophosphamide, n (%)	41 (53.9)	3 (8.8)	<b>&lt;0.001</b>
- Plasma exchanges, n (%)	25 (32.9)	7 (20.6)	0.28
<b>Renal parameters at last follow-up</b>			
- Proteinuria > 0.5 g/d, n (%)	12 (19)	5 (14.7)	0.72
- Hematuria, n (%)	18 (28.6)	5 (14.7)	0.92
- Serum creatinine, mean ± SD	167.1 ± 144.8	149.5 ± 125.2	0.62
- eGFR <sub>LFup</sub> , mean ± SD	50.2 ± 26.1	50.7 ± 21.2	0.94
<b>Clinical response at last follow-up</b>			
-NR, n (%)	16 (17.9)	4 (12.9)	0.52
-PR, n (%)	18 (23.1)	9 (29)	0.69
-CR, n (%)	46 (59)	18 (58.1)	0.90
<b>Overall hematological malignancy</b> , n (%)	28 (35.4)	9 (26.5)	0.48
<b>Severe Infections</b> , n (%)	23 (29.1)	2 (5.9)	<b>0.02</b>
<b>Death</b> , n (%)	19 (24)	5 (14.7)	0.39

SD, standard deviation; g/d, gram/day; eGFR, estimated glomerular filtration rate expressed in mL/min/1.73 m<sup>2</sup>; NR, non-responder; PR, partial remission; CR, complete remission. Bold indicates significant p values.

